Aphios Corporation Awarded Japanese Patent for Phospholipid Nanosomes Technology Platform
May 29, 2008
Woburn, MA — Aphios Corporation today announced that it has been awarded a Japanese Patent No. 4,107,680, issued on April 11, 2008, for its phospholipid nanosomes technology platform for the encapsulation of hydrophobic drugs.

Phospholipid nanosomes are small, uniform liposomes manufactured utilizing SuperFluids™. SuperFluids™ are normally gases which, when compressed, exhibit enhanced solvation, penetration and expansive properties. These fluids are reverse-engineered to form phospholipid nanosomes for encapsulating and improving the delivery of protein therapeutics, vaccine antigens and sRNAi molecules as well as small molecule therapeutics and hydrophobic drugs such as paclitaxel, camptothecin and Bryostatin 1. Dr. Castor, the inventor of this technology platform, points out, "This technology does not utilize organic solvents that could be harmful to the therapeutic, the recipient and/or the environment and is rapid, broadly applicable and scalable while enhancing drug delivery."

Phospholipid nanosomes are nanometer-sized vesicles of phospholipid bilayers comprised of single or multiple lipid bilayers. As such, they are nontoxic, non-antigenic and biodegradable in character since they have the molecular characteristics of mammalian cell membranes. Hydrophilic compounds and therapeutics such as recombinant proteins and sRNAi molecules are encapsulated in the aqueous core while hydrophobic compounds and therapeutics such as anticancer and other water-insoluble drugs are trapped within the lipid bilayers. Encapsulation masks the hydrophobic (water-insoluble) nature of drugs, and permits aqueous, biocompatible formulations to be administered. Phospholipid nanosomes protect the encapsulated therapeutics prolonging their circulation and increasing half-life. For cancer chemotherapy, this increases the likelihood that the drug will reach and destroy cancer cells. Encapsulation also protects cells from the circulating therapeutics and reduces their toxicities. Phospholipid nanosomes could lead to: (i) targeted delivery; (ii) enhancement of therapeutic efficacy; (iii) elimination of pre-medication to counteract toxic excipients; (iv) reduction of drug toxicity side effects; (v) prolongation of circulation time and therapeutic effect; and (vi) improvement in quality of life.

Aphios Corporation is a biopharmaceutical company that is developing enhanced natural therapeutics and biologics for health maintenance, disease prevention and the treatment of human diseases with a focus on cancer, infectious diseases and CNS disorders.